Norfan

Quick links to important sections

Norfan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norfan

What is Norfan? Overview and Identity

Property Description
Active ingredient Amlodipine besylate
Form Oral tablet
Pharmacological class Calcium Channel Blocker (CCB)
General purpose Management of cardiovascular dynamics
Origin Synthetic pharmaceutical

What Type of Medicine is Norfan (Amlodipine)?

Norfan is a prescription-only medication containing the active ingredient Amlodipine besylate, which is classified as a Calcium Channel Blocker (CCB). This medication is defined as a synthetic pharmaceutical compound, specifically belonging to the dihydropyridine subclass of CCBs. This sub-classification indicates that its primary therapeutic effect is focused on relaxing the peripheral blood vessels. Amlodipine is a well-established agent for cardiovascular management and is recognized for its long duration of action. This property makes it an option for stable, once-daily therapeutic effects.

Composition and Drug Form of Norfan

The composition of Norfan relies solely on Amlodipine besylate as the single active compound, delivered via the oral route in tablet form. Amlodipine is formulated as an oral preparation and is combined with solid excipients—inactive structural components—to ensure consistency and stability. This preparation method ensures that the patient receives a precise, uniform dose for systemic absorption, establishing Amlodipine as a single-ingredient therapy.

General Purpose and High-Level Function

The general purpose of Norfan is to reduce cardiovascular strain by allowing blood to flow more easily through the circulatory system. It achieves this by inhibiting the influx of calcium ions into the smooth muscle cells of the arterial walls. This selective action results in the relaxation of blood vessels (vasodilation), which decreases the overall peripheral resistance against which the heart must pump blood. This foundational mechanism is central to the drug's intended role in maintaining healthy blood flow in adult patients.

What side effects are possible with Norfan?

Possible Side Effects and Safety Information

The safety profile of Norfan (Amlodipine) is defined by official regulatory documents, classifying possible adverse reactions by frequency and the body system affected. These classifications reflect how governmental health authorities organize and communicate the medicine’s risk profile, focusing on established regulatory categories.

Frequency-Classified Adverse Reactions

Adverse reactions that are Common (occurring in 1 to 10 out of 100 people) include peripheral oedema (swelling, particularly of the ankles), headache, dizziness, flushing, and fatigue. Reactions classified as Uncommon include insomnia, mood changes, tremor, dry mouth, vomiting, and muscle cramps. The official profile lists several reactions as Very Rare, indicating they occur in less than 1 out of 10,000 people.

System-Organ Classes and Serious Reactions

Side effects are grouped into System-Organ Classes (SOCs), with effects documented across Vascular disorders (flushing, oedema), Nervous system disorders (somnolence, headache), and Cardiac disorders (palpitations, arrhythmia). The regulatory documentation identifies certain serious adverse reactions, including the potential for Worsening Angina or Acute Myocardial Infarction, and severe dermatological events such as Stevens-Johnson Syndrome and Angioedema.

Safety Considerations for Specific Populations

Safety notes specify that Elderly Patients and individuals with Hepatic Impairment may experience decreased clearance and prolonged drug exposure. Official documents also note that caution is required for patients with Severe Heart Failure (NYHA Class III and IV) and those with Severe Aortic Stenosis. Furthermore, reactions like headache and dizziness are noted to occur more frequently at the beginning of treatment.

Safety Restrictions

Norfan is formally contraindicated by regulatory bodies in the presence of known hypersensitivity to the drug or other dihydropyridines, as well as in severe conditions such as Severe Hypotension, Shock (including cardiogenic shock), and specific conditions causing Obstruction of the outflow tract of the left ventricle.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Norfan (Amlodipine besylate) is officially documented in regulatory information as potentially leading to severe and prolonged cardiovascular effects. These manifestations arise from excessive peripheral vasodilation, resulting in profound systemic hypotension (severely low blood pressure) and subsequent circulatory shock.

Documented Manifestations and Severe Outcomes

Classification Manifestation/Outcome
Cardiovascular Signs Prolonged systemic hypotension, bradycardia (slowed heart rate), compensatory tachycardia (rapid heart rate), and syncope (fainting).
Life-Threatening Outcomes Cardiovascular decompensation, intractable lactic acidosis, and potentially fatal outcomes in refractory cases.

Official Emergency Actions Required

Regulatory documents state that a suspected overdose requires immediate medical attention. You must call emergency services if the affected person collapses, has trouble breathing, or cannot be awakened. Hospital monitoring and active cardiac and respiratory monitoring are essential due to the long elimination half-life of Amlodipine.

Management is strictly symptomatic and supportive, as no specific antidote is known. Supportive measures include elevating the extremities, administering intravenous fluids, and using vasopressors (such as phenylephrine) if hypotension persists. Hemodialysis is not considered an effective treatment due to the drug’s high protein binding.

Therapeutic Uses of Norfan

Norfan is generally used for managing a variety of symptoms related to physical discomfort, fever, and conditions involving inflammatory or irritative processes. It may be part of symptomatic management applied across domains where additional symptomatic support is needed.

The medication is commonly used to help with temporary symptomatic relief for mild to moderate pain. This may assist with common conditions, including headaches, minor pain of arthritis, toothaches, backaches, menstrual cramps (primary dysmenorrhea), and muscle aches. It is relevant for easing symptoms related to systemic imbalance by helping to reduce fever.

The support Norfan provides contributes to easing the overall symptom burden in situations where symptoms become more noticeable. “It may assist with providing supportive relief when symptoms interfere with routine activities.”

Quick Fact: Relief for Symptoms that interfere with daily functioning

As a Nonsteroidal Anti-inflammatory Drug (NSAID), Norfan is also considered relevant for addressing symptoms related to inflammatory or irritative states. It is used in conditions characterized by heightened symptoms of inflammation, such as rheumatoid arthritis and osteoarthritis. The support Norfan provides assists with maintaining functional stability during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of Ibuprofen

Eligibility and Restrictions for Use

Norfan (Amlodipine besylate) is subject to strict eligibility rules that define its authorized use based on governmental regulatory labeling.

Populations Who Must Not Use Norfan (Contraindicated)

Use of this medicine is absolutely prohibited in patients with known hypersensitivity to amlodipine or any dihydropyridine derivatives. It is also contraindicated in patients experiencing severe hypotension or a state of shock, including cardiogenic shock. Individuals with obstruction of the outflow tract of the left ventricle (such as high-grade aortic stenosis) or haemodynamically unstable heart failure after a recent heart attack are also excluded from use.

Specific Population and Condition Restrictions

Eligibility Factor Regulatory Status
Age Approved for adults and adolescents with hypertension aged 6 to 17 years. Use is not established for children under the age of 6.
Hepatic Function Patients with hepatic impairment require use with caution. Dosage should be started at the low end of the range.
Renal Function Use is allowed for patients with renal impairment; no dose adjustment is typically required.
Pregnancy/Lactation In pregnancy, use is permitted only if the potential benefit justifies the risk. Regulatory authorities advise discontinuing breastfeeding when taking this medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Norfan (Amlodipine) defines its interaction structure primarily through documented pharmacokinetic changes that modify drug exposure and pharmacodynamic reinforcement that leads to additive physiological effects. These documented changes result in specific label constraints and prohibitions on certain substance combinations. The profile is further structured by population-specific notes regarding clearance.

Pharmacokinetic and Exposure Constraints

  • Co-administration with strong or moderate CYP3A4 inhibitors causes a significant increase in Norfan systemic exposure (plasma concentrations).
  • Norfan increases the systemic exposure of Simvastatin, which requires a regulatory constraint that the Simvastatin dose must not exceed 20 mg daily.
  • Norfan may also increase the systemic exposure of Immunosuppressants (e.g., Tacrolimus, Cyclosporine), necessitating monitoring of blood levels.

Pharmacodynamic Effects and Specific Restrictions

  • The combination with intravenous Dantrolene should generally be avoided due to the associated risk of hyperkalemia.
  • Grapefruit or Grapefruit Juice consumption is not recommended as it may increase amlodipine bioavailability.
  • Co-administration with Sildenafil or other blood pressure-lowering agents may result in an additive hypotensive effect.
  • Population-Specific Note: The label mandates slow dose titration in patients with severe hepatic impairment due to the drug's prolonged clearance in this population.

Mechanism of Action

Norfan primarily acts within the central nervous system by targeting neuronal cell membranes. The molecule functions as an inhibitor of the sodium-dependent norepinephrine transporter (NET) and, to a lesser extent, the sodium-dependent serotonin transporter (SERT) within presynaptic terminals. This competitive blockade impedes the reuptake of the neurotransmitters norepinephrine and serotonin from the synaptic cleft.

Downstream, the diminished reuptake activity elevates the synaptic concentration of these monoamines, prolonging their interaction with their respective postsynaptic adrenergic and serotonergic receptors. Furthermore, Norfan displays antagonist activity at several other receptor subtypes, including muscarinic acetylcholine receptors (mAChR), histamine H1 receptors, and certain 5-hydroxytryptamine receptors (5-HT receptors).

This broad modulation of central neurotransmission is associated with system-level physiological changes, particularly within the ascending and descending monoaminergic pathways. This includes modulation of pain signal transmission and central autonomic regulation, which alters the excitability and signaling thresholds of involved neurons.

Dosage and Administration Information

How to Use Norfan: Official Administration Guidelines

Norfan (Amlodipine besylate) is administered according to specific, standardized instructions. These guidelines govern the route of intake, dosing schedules, and adjustments for specific patient groups, ensuring procedural consistency across its use.


Administration Scope

Entity Detail
Route of administration Oral (by mouth).
Dosing schedule (Adults) Initial Dose: 5 mg once daily. Maintenance Dose: 5 mg to 10 mg once daily. Maximum Dose: 10 mg once daily.
Timing in relation to meals May be taken with or without food, as its absorption is not altered.
Missed-dose rules If a dose is missed, take it as soon as remembered that day. Do not take two doses at once to make up for a missed dose.
Age-group administration rules Older Adults: A lower initial dose of 2.5 mg once daily may be considered. Pediatric (6–17 years): The starting dose is 2.5 mg once daily, with a maximum dose of 5 mg once daily.

Resulting Procedural Structure

The medicine is designed for once-daily dosing, requiring the patient to establish a consistent 24-hour interval between administrations. The official protocol dictates a cautious approach to dose modification, with adjustments (titration) generally proceeding over a period of 7 to 14 days to fully assess the body's response before changing the dose. This ensures that Norfan is used as a long-term, carefully managed oral therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Norfan (Amlodipine)

This overview summarizes the official research evidence used by regulatory bodies to evaluate Norfan (Amlodipine), focusing on the types of studies conducted, the outcomes measured, and the consistency and limitations documented in the scientific literature. This information provides context on the research landscape and is not intended to provide clinical guidance or treatment recommendations.

Evidence for use in High Blood Pressure (Hypertension)

Research related to Norfan's role in high blood pressure is evaluated using a large volume of clinical data. Researchers primarily conducted large-scale Randomized Controlled Trials (RCTs) and long-term studies that monitored changes related to systemic or functional imbalance. Studies examined outcomes related to physiological strain or stress, specifically measuring the change in systolic and diastolic blood pressure (BP). Long-term outcome trials were used to compare Norfan-based regimens against other treatment strategies, with studies exploring the incidence rates of major events such as heart attack and stroke. Follow-up durations were limited for some subgroups in outcome analyses.

Evidence for Managing Angina and Coronary Artery Disease (CAD)

Research has explored Norfan in conditions related to coronary artery disease (CAD), specifically chronic stable angina and vasospastic angina. Research exploring symptomatic changes was primarily assessed in short-term, placebo-controlled clinical trials. These studies examined endpoints related to patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level, such as exercise capacity. Trials described patterns observed in the recorded frequency of angina attacks.

Specific long-term outcome trials were also conducted for adults with documented CAD who did not have heart failure. These studies compared the incidence rate of certain procedural and hospitalization endpoints against placebo. However, reports examining surrogate markers indicated findings were mixed or inconsistent.

What is Still Uncertain About Norfan

An important limitation is that data for certain groups remain insufficient. Regulatory documents state that the effect of Amlodipine on blood pressure in patients less than 6 years of age is not known, as research is ongoing for this age group. Furthermore, research focusing on angina is primarily centered on short-term symptomatic relief, and these studies did not fully explore long-term effects on mortality.

Key Studies & References

  1. highlights of prescribing information (Amlodipine/Atorvastatin combination label)

Frequently Asked Questions (FAQ)

Common questions about Norfan (FAQ)


Q: Is Norfan an antibiotic?

A: No, Norfan is not an antibiotic. According to official regulatory documents, it is classified as a Calcium Channel Blocker (CCB), a type of medicine used for cardiovascular conditions like high blood pressure and certain kinds of angina. It is not indicated for the treatment of bacterial infections.


Q: Can Norfan be used for pain relief?

A: Norfan is officially approved and indicated for the treatment of high blood pressure and specific types of angina (chest pain associated with heart conditions). Official regulatory information does not list Norfan for general pain relief. Its use is focused on managing cardiovascular symptoms.


Q: Does Norfan make you sleepy?

A: Official product information lists sleepiness (somnolence) as a common side effect. This means that up to 1 in 10 people may experience it, particularly when treatment is first started. If somnolence occurs, this is a factor that may require consideration.


Q: Is it normal to feel dizzy after taking Norfan?

A: Yes, regulatory documents classify dizziness as a common side effect of Norfan. This indicates that it is a known and frequently documented effect, potentially affecting up to 1 in 10 people. Dizziness may be more noticeable at the beginning of treatment.


Q: Can Norfan interact with blood thinners?

A: While regulatory documents do not specify a known significant interaction between Norfan and the common blood thinner warfarin, co-administration with other medicines that affect blood pressure may have additive effects. Regulatory guidance emphasizes the importance of a patient's healthcare provider being aware of all medications being taken.


Q: Can I drink alcohol while taking Norfan?

A: It is noted in patient guidance that alcohol may have an additive effect in lowering blood pressure when combined with Norfan. This combination could increase the risk of symptoms like lightheadedness, dizziness, or fainting. Using caution when consuming alcohol is a common consideration when taking this type of medication.


Q: Does Norfan affect driving ability?

A: Because Norfan can cause known side effects such as dizziness, headache, or tiredness, regulatory guidance advises consideration of caution regarding driving or operating machinery until the medicine’s full effect is understood.


Q: What should I do if a side effect seems mild?

A: For mild and expected side effects, official patient guidance often references simple measures like resting and ensuring adequate fluid intake. If a side effect is persistent, worsening, or bothersome, a patient may choose to discuss the effect with a healthcare provider.


Q: Can Norfan interact with common over-the-counter cold medicines?

A: The official interaction profile is complex. While not all cold medicines are listed, many contain ingredients like sympathomimetic agents (e.g., decongestants) that can raise blood pressure, which may counteract the intended effect of Norfan. Consideration of potential effects is part of managing treatment when taking such combinations.


Q: What happens if Norfan is taken with too much caffeine?

A: Official labeling does not contain a specific warning regarding caffeine. However, Norfan works to lower blood pressure, and high amounts of caffeine may increase blood pressure. It is important to be mindful of this potential opposing physiological effect.


Q: Can Norfan interact with vitamins?

A: Regulatory information primarily focuses on prescription drug interactions. There is no blanket warning against all vitamins, but some documents have noted that certain multivitamins containing minerals may potentially decrease the effect of Norfan. Patients are encouraged to share information about any supplements being taken with their healthcare provider.


Q: Do people typically stop Norfan due to side effects?

A: Clinical trial data indicates that the rate of patients discontinuing Norfan treatment due to adverse reactions is typically low. While certain side effects like swelling may lead to discontinuation in some patients, the majority of people in studies were able to continue treatment.


Q: Can Norfan be taken during breastfeeding?

A: Regulatory documents recommend discontinuing breastfeeding when using Norfan. This recommendation is made because it has not been established whether the medicine is excreted into human breast milk.


Q: How long until Norfan starts working?

A: Official clinical pharmacology data indicates that after taking a single oral dose, Norfan begins its action of lowering blood pressure. The peak concentration of the drug in the blood, where the maximum effect is typically observed, occurs between 6 and 12 hours after administration.


Q: How long does the effect of Norfan last in the body?

A: Norfan is designed to be a long-acting medicine, with its therapeutic effects lasting for at least 24 hours to support once-daily dosing. The medication has a long terminal elimination half-life, reported to be between 30 and 50 hours.


Q: Can Norfan interfere with birth control pills?

A: Regulatory documentation has established that there are no known or stated interactions between Norfan and standard oral contraceptives (birth control pills) that would affect the efficacy of the contraceptives.


Q: Why is Norfan sometimes prescribed instead of other options?

A: Norfan is valued in cardiovascular management due to its classification as a long-acting Calcium Channel Blocker (CCB). This pharmacological property supports a stable therapeutic effect that is reliably maintained over a 24-hour period, which makes it suitable for once-daily dosing.


Q: Is Norfan only for temporary use?

A: Treatment with Norfan is generally considered a long-term therapy. It is designed for the ongoing management of chronic conditions such as high blood pressure and angina, rather than short-term use.


Q: Is it possible to develop a tolerance to Norfan?

A: In clinical studies, regulatory evidence has shown that the development of tolerance to Norfan's effects was not demonstrated in patients studied for up to one year of continuous use.


Q: Are there different strengths or formulations of Norfan?

A: According to official documentation, Norfan is primarily available as oral tablets in specific strengths. These typically include 2.5 mg, 5 mg, and 10 mg tablets. Other formulations, like liquid solutions, may also be available.


Q: Does Norfan need to be tapered off when stopping?

A: Official guidance advises that patients should not suddenly stop taking Norfan. Abrupt discontinuation may potentially cause an increase in blood pressure or chest pain. Discussions about the decision to stop treatment and the necessary procedure are handled by a healthcare provider.


Q: Why is Norfan a prescription-only drug?

A: Norfan is classified as a prescription-only medicine because it is used for the management of serious, long-term cardiovascular conditions. Its classification suggests a need for medical supervision and monitoring for appropriate use, evaluation of effects, and safety considerations.


Q: Can Norfan affect your liver?

A: Regulatory documents note that caution is required in patients with hepatic impairment (reduced liver function), as the drug's clearance is decreased in this population. Rare adverse reactions have included increases in liver enzymes, which can be an indicator of liver stress.


Q: Does Norfan cause weight gain?

A: Official regulatory adverse reaction lists include both weight gain and weight decrease as possible effects. These are noted to occur with an unknown frequency in some patients using the medication.


Q: Does Norfan have an effect on mood or anxiety?

A: Official regulatory documents list mood changes, anxiety, and depression as uncommon side effects of Norfan. While not common, these are noted as potential effects that may occur.

How should Norfan be stored and disposed of?

How to Store and Dispose of Norfan (Amlodipine)

Norfan (Amlodipine besylate) must be stored under specific conditions to maintain its stability. The official requirement is to store the tablets at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to keep the container tightly closed and protect the medicine from moisture and heat. Do not store the medicine in moist areas, such as a bathroom.

Official Disposal Instructions

For disposal, the product must not be kept if it is outdated or no longer needed. The official guidance requires the use of a medicine take-back program. If a program is unavailable, the unused tablets must be removed from the container, mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed bag, and then discarded in the household trash. The medicine must not be flushed down a toilet or poured down a drain. It is also required to keep Norfan out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Norfan found in:

A-Z Index: